Evidently, any interference of this interaction either by a specific shRNA to SEPT9_i1 [20] or by a SEPT9_i1 N-terminal peptide, which competes with SEPT9_i1 in the interaction with the nuclear transporter importin-α [21], decreases HIF-1 activation, tumor progression and angiogenesis. The gene discussed is SETD2; the disease is neoplasm.